IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
IMAC Holdings (NASDAQ: BACK) has launched Ignite Proteomics , a subsidiary focused on protein-based cancer treatment selection. The new venture aims to disrupt the multi-billion-dollar genomic testing market, with an immediate addressable market of $600M in its current clinically approved indication.
Unlike traditional genomic testing, Ignite's multi-protein test provides real-time insights into tumor behavior and drug response, particularly for antibody-drug conjugates (ADCs) and immunotherapies. The platform features novel biomarkers protected by licensed patents, offering physicians enhanced capabilities to select effective treatments and avoid trial-and-error approaches.
The company is actively collaborating with leading cancer centers to expand clinical evidence and integrate its test into routine care. The platform is particularly focused on breast cancer treatment guidelines and aims to provide more accurate insights than traditional gene-based testing methods.
IMAC Holdings (NASDAQ: BACK) ha lanciato Ignite Proteomics, una sussidiaria focalizzata sulla selezione dei trattamenti contro il cancro basati sulle proteine. Il nuovo progetto mira a rivoluzionare il mercato dei test genomici da miliardi di dollari, con un mercato immediatamente indirizzabile di 600 milioni di dollari nella sua attuale indicazione clinicamente approvata.
A differenza dei test genomici tradizionali, il test multi-proteico di Ignite fornisce informazioni in tempo reale sul comportamento del tumore e sulla risposta ai farmaci, in particolare per i coniugati farmaco-anticorpo (ADC) e le immunoterapie. La piattaforma presenta biomarcatori innovativi protetti da brevetti concessi in licenza, offrendo ai medici capacità migliorate per selezionare trattamenti efficaci ed evitare approcci basati su tentativi ed errori.
L'azienda sta attivamente collaborando con i principali centri oncologici per espandere le evidenze cliniche e integrare il suo test nella cura di routine. La piattaforma è particolarmente focalizzata sulle linee guida per il trattamento del cancro al seno e mira a fornire informazioni più accurate rispetto ai metodi di test basati sui geni tradizionali.
IMAC Holdings (NASDAQ: BACK) ha lanzado Ignite Proteomics, una subsidiaria centrada en la selección de tratamientos contra el cáncer basados en proteínas. La nueva empresa tiene como objetivo interrumpir el mercado de pruebas genómicas de miles de millones de dólares, con un mercado inmediatamente direccionable de 600 millones de dólares en su indicación clínica actualmente aprobada.
A diferencia de las pruebas genómicas tradicionales, la prueba multiproteica de Ignite proporciona información en tiempo real sobre el comportamiento del tumor y la respuesta a los medicamentos, particularmente para los conjugados anticuerpo-fármaco (ADC) y las inmunoterapias. La plataforma cuenta con biomarcadores novedosos protegidos por patentes licenciadas, ofreciendo a los médicos capacidades mejoradas para seleccionar tratamientos efectivos y evitar enfoques de prueba y error.
La empresa está colaborando activamente con los principales centros oncológicos para expandir la evidencia clínica e integrar su prueba en la atención rutinaria. La plataforma se centra especialmente en las pautas de tratamiento del cáncer de mama y tiene como objetivo proporcionar información más precisa que los métodos de prueba basados en genes tradicionales.
IMAC Holdings (NASDAQ: BACK)가 Ignite Proteomics를 출시했습니다. 이 자회사는 단백질 기반의 암 치료 선택에 집중하고 있습니다. 새로운 사업은 수십억 달러 규모의 유전자 검사 시장을 혁신하는 것을 목표로 하며, 현재 임상에서 승인된 적응증에 대해 즉각적인 이용 가능 시장이 6억 달러입니다.
전통적인 유전자 검사와 달리, Ignite의 다단백질 검사는 종양의 행동과 약물 반응에 대한 실시간 통찰력을 제공합니다. 특히 항체-약물 접합체 (ADC) 및 면역 요법에 관한 것입니다. 이 플랫폼은 라이선스가 부여된 특허로 보호되는 혁신적인 바이오 마커를 특징으로 하며, 의사들에게 효과적인 치료를 선택하고 시행착오 접근 방식을 피할 수 있는 향상된 능력을 제공합니다.
회사는 주요 암 센터와 적극적으로 협력하여 임상 증거를 확장하고 자신의 검사를 일상적인 치료에 통합하고 있습니다. 이 플랫폼은 특히 유방암 치료 가이드라인에 집중하고 있으며, 전통적인 유전자 기반 검사 방법보다 더 정확한 통찰력을 제공하는 것을 목표로 하고 있습니다.
IMAC Holdings (NASDAQ: BACK) a lancé Ignite Proteomics, une filiale axée sur la sélection des traitements contre le cancer basés sur les protéines. Ce nouveau projet vise à perturber le marché des tests génomiques de plusieurs milliards de dollars, avec un marché immédiatement accessible de 600 millions de dollars dans son indication clinique actuellement approuvée.
Contrairement aux tests génomiques traditionnels, le test multi-protéines d'Ignite fournit des informations en temps réel sur le comportement des tumeurs et la réponse aux médicaments, en particulier pour les conjugués anticorps-médicaments (ADC) et les immunothérapies. La plateforme dispose de biomarqueurs novateurs protégés par des brevets sous licence, offrant aux médecins des capacités améliorées pour sélectionner des traitements efficaces et éviter les approches d'essai-erreur.
La société collabore activement avec des centres de cancérologie de premier ordre pour étendre les preuves cliniques et intégrer son test dans les soins de routine. La plateforme se concentre particulièrement sur les directives de traitement du cancer du sein et vise à fournir des informations plus précises que les méthodes de test basées sur les gènes traditionnels.
IMAC Holdings (NASDAQ: BACK) hat Ignite Proteomics gegründet, eine Tochtergesellschaft, die sich auf die Auswahl von proteinbasierten Krebsbehandlungen konzentriert. Das neue Unternehmen zielt darauf ab, den milliardenschweren Markt für genomische Tests zu revolutionieren, mit einem sofort ansprechbaren Markt von 600 Millionen Dollar in seiner derzeit klinisch genehmigten Indikation.
Im Gegensatz zu traditionellen genomischen Tests bietet der Multi-Protein-Test von Ignite Echtzeiteinblicke in das Tumorverhalten und die Arzneimittelreaktion, insbesondere bei Antikörper-Wirkstoff-Konjugaten (ADCs) und Immuntherapien. Die Plattform weist neuartige Biomarker auf, die durch lizenzierte Patente geschützt sind, und bietet den Ärzten verbesserte Möglichkeiten zur Auswahl effektiver Behandlungen und zur Vermeidung von Versuch-und-Irrtum-Ansätzen.
Das Unternehmen arbeitet aktiv mit führenden Krebszentren zusammen, um klinische Evidenz auszubauen und seinen Test in die routinemäßige Versorgung zu integrieren. Die Plattform konzentriert sich insbesondere auf die Leitlinien zur Behandlung von Brustkrebs und zielt darauf ab, genauere Einblicke als traditionelle genbasierte Testmethoden zu bieten.
- Addressable market of $600M in current clinically approved indication
- Protected intellectual property through licensed patents for novel biomarkers
- Active collaborations with leading cancer centers
- Positioning to disrupt multi-billion-dollar genomic testing market
- None.
Insights
The launch of Ignite Proteomics marks a transformative strategic shift for IMAC Holdings, positioning the company in the rapidly growing precision oncology diagnostics market. The $600M addressable market opportunity in the initial indication represents significant revenue potential, particularly given the company's current market cap of
The technology's focus on protein-level analysis addresses a critical gap in current genomic testing approaches, particularly for modern cancer therapies like ADCs and immunotherapies. This differentiation is important as these therapeutic classes are experiencing explosive growth - the global ADC market alone is projected to reach
Several key factors strengthen the commercial potential:
- Patent protection on novel biomarkers creates significant barriers to entry
- Ongoing collaborations with leading cancer centers will help build clinical evidence and drive adoption
- Focus on breast cancer as the initial indication provides a clear path to market
- Potential inclusion in treatment guidelines could drive widespread adoption and reimbursement
However, investors should consider key execution risks:
- The diagnostic market is highly competitive with established players
- Clinical validation and regulatory approval timelines could impact commercialization
- Reimbursement negotiations with payers will be critical for adoption
- Significant investment may be needed for commercial infrastructure
The strategic value proposition is compelling - by addressing limitations in current testing approaches and focusing on high-growth therapeutic areas, Ignite Proteomics could capture significant market share. The technology's ability to provide deeper insights into tumor biology and drug response could make it an essential tool in oncology treatment planning.
Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond.
Why Proteins Matter – Beyond Genomics
Although genomics (gene-based) testing has become common, patients and providers find it has not fully delivered on the promise of personalized care. One reason is that genetics only reveal potential – the blueprint of the disease – while proteins show what is happening inside cancer cells right now. Ignite is poised to disrupt the multi-billion-dollar genomic testing market. The available market in the test’s current clinically approved indication is
Proteins drive cell behavior and are the direct targets of many new cancer drugs, especially antibody-drug conjugates (ADCs) and immunotherapies. Without measuring key proteins, standard genomic tests can miss crucial signals that predict how a tumor will respond – or fail to respond – to treatment.
Ignite’s multi-protein test addresses this gap. By measuring a range of proteins in a single sample, it offers a richer view of a tumor’s activity and vulnerability to specific therapies. Several of the assay’s important novel biomarkers are protected by licensed patents, ensuring a unique platform for guiding advanced treatment choices.
“Gene tests alone don’t tell us enough about how to pick the right therapies,” said Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics. “Proteins are what guide a cancer’s behavior and drug response. Our test focuses on these real-time signals, so doctors can better select complex treatments right from the start.”
A Better Approach to Modern Cancer Treatments
Today’s advanced therapies—from new ADCs to immunotherapies—are more complex than traditional chemo. Standard “one-marker” tests often fail to identify which patients can truly benefit. Ignite’s test reviews multiple critical proteins at once, helping physicians:
- Spot lower levels of drug targets that standard methods might overlook.
- Determine whether an immunotherapy is likely to work—or if a patient would do better with another option.
- Avoid the costly and time-consuming trial-and-error approach that can delay effective treatment.
Looking Ahead: Partnerships & Growth
- Active Collaborations: Ignite is working with leading cancer centers to expand clinical evidence and incorporate its test into more routine care.
- Expanding Impact: The test’s ability to measure what genes alone cannot detect is expected to fill a major gap in personalized oncology.
- Focus on ADCs & Immunotherapy: With more complex drugs rolling out each year, physicians need deeper insights into a tumor’s real-time behavior—and that is exactly where Ignite’s protein-level approach excels.
- Standard of care: Ignite’s protein analysis has generated and is expanding clinical data needed to be included in treatment guidelines for breast cancer.
About IMAC Holdings, Inc.
IMAC Holdings, Inc. strives to improve patient outcomes through innovative healthcare solutions. By combining strategic acquisitions and innovative technologies, IMAC Holdings remains committed to advancing personalized medicine. IMAC Holdings has begun the process to change its name and will soon be shown as IMAC Holdings, Inc, DBA Ignite Sciences, Inc.
About Ignite Proteomics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, specializes in protein-based analysis for cancer treatment guidance. Operating under a CLIA-accredited lab, Ignite provides a single test covering multiple markers to help doctors pinpoint the most suitable therapies, bridging the gap that gene-focused methods leave behind. Several key markers in the assay are protected by licensed patents.
Forward-Looking Statements
This press release contains statements that involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ. Readers are cautioned not to place undue reliance on these statements. For more information, please review the Company’s SEC filings.
Contact Information:
Investors@imacholdings.com
FAQ
What is the market opportunity for IMAC Holdings' (BACK) Ignite Proteomics?
How does IMAC Holdings' (BACK) Ignite protein test differ from traditional genomic testing?
What types of cancer treatments does IMAC Holdings' (BACK) Ignite test specifically target?
What partnerships has IMAC Holdings (BACK) established for Ignite Proteomics?
What is the current clinical focus of IMAC Holdings' (BACK) Ignite platform?
